Correction of experimental dislipoproteinemia by the intranasal administration of an original enzyme preparation

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article is devoted to the experimental study of the specific pharmacological activity of the original microbial cholesterol oxidase enzyme preparation obtained from Streptomices lavendulae. In the condition of modeling dyslipoproteinemia, a pronounced alimentary hyperlipidemia in rats with the intranasal route of administration, a dose-dependent lipid-lowering effect of the domestic enzyme preparation of microbial origin of cholesterol oxidase was detected. In moderate alimentary hyperlipidemia, based on the selection of animals with a difficultly developed conditioned drinking reflex, this original preparation of cholesterol oxidase in an effective dose has a hypolipidemic effect and normalization of the serum lipoprotein spectrum. Further studies are needed to finally clarify the question of the character, efficacy and hypolipidemic action of the natural-produced cholesterol oxidase test drug in other types of animals.

Full Text

Restricted Access

About the authors

Natalia N. Klyueva

Institute of Experimental Medicine

Author for correspondence.
Email: nnklyueva@gmail.com

PhD (Biochemistry), Researcher, Department of Biochemistry

Russian Federation, Saint Petersburg

Irina V. Okunevich

Institute of Experimental Medicine

Email: irina_okunevich@mail.ru

PhD (Pharmacology), Senior Researcher

Russian Federation, Saint Petersburg

Nina S. Parfenova

Institute of Experimental Medicine

Email: nnklyueva@gmail.com

PhD (Biochemistry), Senior Researcher. Department of Biochemistry

Russian Federation, Saint Petersburg

Petr D. Shabanov

Institute of Experimental Medicine

Email: pdshabanov@mail.ru

Dr. Med. Sci. (Pharmacology), Professor and Head, Dept. of Neuropharmacology

Russian Federation, Saint Petersburg

References

  1. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines: the task force for management of dyslipidemias of the European Society of Cardiology (EAC) and European Atherosclerosis Society (EAS). Eur Heart J. 2016;37: 2999-3058. https://doi.org/10.1093/eurheartj/ehw272.
  2. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170.000 patients in 26 randomised trials. Lancet. 2010;376:1670-1681. https://doi.org/10.1016/S0140-6736(10)61350-5.
  3. Бубнова М.Г., Аронов Д.М., Деев А.Д. Терапия статинами в реальной клинической практике у пациентов с гиперлипидемией и коронарной болезнью сердца. Российская программа ЭФФОРТ // Атеросклероз и дислипидемии. – 2018. – № 1. – С. 5–16. [Bubnova MG, Aronov DM, Deev AD. Statins in routine clinical care in elderly with hyperlipidemia and coronary heart disease. Russian program EFFORT. Atherosclerosis and dyslipidemias. 2018;(1):5-16. (In Russ.)]
  4. Зыков М.В. Проблема безопасности липидснижающей терапии // Кардиология. – 2019. – Т. 59. – № S5. – C. 13–26. [Zykov MV. The problem of the safety of lipid-lowering therapy. Cardiology. 2019;59(S5):13-26. (In Russ.)]. https://doi.org/10.18087/cardio.2505.
  5. Хохлов П.П., Тиссен И.Ю., Лебедев А.А., и др. Содержание орексина А в структурах головного мозга крыс коррелирует с паттернами поведения у стрессированных крыс // Обзоры по клинической фармакологии и лекарственной терапии. – 2018. – Т. 16. – № 4. – С. 45–48. [Khokhlov PP, Tissen IYu, Lebedev AA, et al. Orexin A content in brain structures correlates with behavioral patterns in stressed rats. Reviews on clinical pharmacology and drug therapy. 2018;16(4):45-48. (In Russ.)]. https://doi.org/10.17816/RCF16445-48.
  6. Шевченко К.В., Вьюнов Т.В., Андреева Л.А., и др. Сравнение фармакокинетики и метаболизма Pro-Gly-Pro-Leu в крови и мозге крыс при интраназальном и внутривенном введении // Доклады академии наук. – 2014. – Т. 456. – № 5. – С. 613. [Shevchenko KV, V’yunov TV, Andreeva LA, et al. Comparison of pharmacokinetics and metabolism of Pro-Gly-Pro-Leu administered intranasally and intravenously in the blood and brain of rats. Doklady Biochemistry and Biophysics. 2014;456(5):613. (In Russ.)]. https://doi.org/10.7868/S0869565214170290.
  7. Демина Н.Б., Бахрушина Е.О., Бардаков А.И., Краснюк И.И. Биофармацевтические аспекты дизайна интраназальных лекарственных форм // Фармация. – 2019. – Т. 68. – № 3. – С. 12–17. [Demina NB, Bakhrushina EO, Bardakov AI, Krasnyuk II. Design of intranasal dosage forms: biopharmaceutical aspects. Pharmacia. 2019;68(3):12-17. (In Russ.)]. https://doi.org/10/29296/25419218-2019-03-02.
  8. Клюева Н.Н., Рыженков В.Е., Сапронов Н.С. Возможность экспериментального индуцирования гиперхолестеринемии у крыс с трудно выработанным питьевым рефлексом // Российский физиологический журнал им. И.М. Сеченова. – 1997. – Т. 83. – № 3. – С. 105–111. [Kliueva NN, Ryzhenkov VE, Sapronov NS. Ability to induce an experimental hypercholesteremia in rats with reduced ability for drinking conditioning. Rossiyskiy fiziologicheskiy zhurnal im. I.M. Sechenova. 1997;83(3):105-111. (In Russ.)]
  9. Клюева Н.Н., Окуневич И.В., Белова Е.В. Использование модели гиперхолестеринемии у крыс с низкой способностью к выработке условного рефлекса при скрининге гиполипидемических препаратов // Психофармакология и биологическая наркология. – 2007. – Т. 7. – № 4. – С. 1727–1728. [Klyuyeva NN, Okunevich IV, Belova YeV. Ispol’zovaniye modeli giperkholesterinemii u krys s nizkoy sposobnost’yu k vyrabotke uslovnogo refleksa pri skrininge gipolipidemicheskikh preparatov. Psychopharmacology and Biological Narcology. 2007;7(4):1727-1728. (In Russ).]

Copyright (c) 2020 Klyueva N.N., Okunevich I.V., Parfenova N.S., Shabanov P.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 65565 от 04.05.2016 г.